Phase II trial of elraglusib, a GSK-3ß inhibitor, in untreated mPDAC

4 Views

  • Thanks! Share it with your friends!

    You disliked this video. Thanks for the feedback!

admin
Published
Devalingam Mahalingam, MD, PhD, Northwestern University, Evanston, IL, discusses the Phase II Actuate 1801 trial (NCT03678883) of gemcitabine and nab-paclitaxel with or without elraglusib, a first-in-class inhibitor of GSK-3ß, in previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC). Early data suggest improved 1-year and median overall survival in patients receiving elraglusib, alongside trends toward better disease control and response. The safety profile was manageable, though certain grade ≥3 toxicities were more frequent. Biomarker analyses, including interferon beta and PD-L1, may offer prognostic insights pending final data. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Category
Oncology
Be the first to comment

Up Next